The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
The Role of Human Carboxylesterases in Drug Metabolism: Have We Overlooked Their Importance?
Open accessAbstract
Carboxylesterases are a multigene family of mammalian enzymes widely distributed throughout the body that catalyze the hydrolysis of esters, amides, thioesters, and carbamates. In humans, two carboxylesterases, hCE 1 and hCE 2, are important mediators of drug metabolism. Both are expressed in the liver, but hCE 1 greatly exceeds hCE 2. In the intestine, only hCE 2 is present and highly expressed. The most common drug substrates of these enzymes are ester prodrugs specifically designed to enhance oral bioavailability by hydrolysis to the active carboxylic acid after absorption from the gastrointestinal tract. Carboxylesterases also play an important role in the hydrolysis of some drugs to inactive metabolites. It has been widely believed that drugs undergoing hydrolysis by hCE 1 and hCE 2 are not subject to clinically significant alterations in their disposition, but evidence exists that genetic polymorphisms, drug‐drug interactions, drug‐disease interactions and other factors are important determinants of the variability in the therapeutic response to carboxylesterase‐substrate drugs. The implications for drug therapy are far‐reaching, as substrate drugs include numerous examples from widely prescribed therapeutic classes. Representative drugs include angiotensin‐converting enzyme inhibitors, angiotensin receptor blockers, antiplatelet drugs, statins, antivirals, and central nervous system agents. As research interest increases in the carboxylesterases, evidence is accumulating of their important role in drug metabolism and, therefore, the outcomes of pharmacotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
THE MAMMALIAN CARBOXYLESTERASES: From Molecules to Functions
Satoh, T., & Hosokawa, M. (1998) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.257 · Cited by 758
The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans
Blech, S., Ebner, T., Ludwig-Schwellinger, E., Stangier, J., & Roth, W. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.019083 · Cited by 689
Structure, function and regulation of carboxylesterases
Satoh, T., & Hosokawa, M. (2006) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2006.07.001 · Cited by 488
Clinical Pharmacokinetics of the Prodrug Oseltamivir and its Active Metabolite Ro 64-0802
He, G., Massarella, J., & Ward, P. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199937060-00003 · Cited by 410
Farid, N. A., Kurihara, A., & Wrighton, S. A. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009343005 · Cited by 397
Hosokawa, M. (2008) · Molecules · doi:10.3390/molecules13020412 · Cited by 382
Structure, Function, and Regulation of Carboxylesterases
Hosokawa, M., & Satoh, T. (2006) · Toxicology of Organophosphate & Carbamate Compounds · doi:10.1016/b978-012088523-7/50017-x · Cited by 374
Human Carboxylesterase Isozymes: Catalytic Properties and Rational Drug Design
Imai, T. (2006) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.21.173 · Cited by 359
Current Progress on Esterases: From Molecular Structure to Function
Satoh, T., Taylor, P., Bosron, W. F., Sanghani, S. P., Hosokawa, M., & Du, B. N. L. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.5.488 · Cited by 295
Shi, D., Yang, J., Yang, D., LeCluyse, E. L., Black, C., Li, Y., Akhlaghi, F., & Yan, B. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.111807 · Cited by 279
Cited by
The expanding role of prodrugs in contemporary drug design and development
Rautio, J., Meanwell, N. A., Di, L., & Hageman, M. J. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.46 · Cited by 767
Human carboxylesterases: a comprehensive review
Wang, D., Zou, L., Jin, Q., Hou, J., Ge, G., & Yang, L. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.05.005 · Cited by 543
de Man, F. M., Goey, A. K. L., van Schaik, R. H. N., Mathijssen, R. H. J., & Bins, S. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0644-7 · Cited by 421
Carboxylesterases in lipid metabolism: from mouse to human
Lian, J., Nelson, R., & Lehner, R. (2018) · Protein & Cell · doi:10.1007/s13238-017-0437-z · Cited by 300
Prodrugs in medicinal chemistry and enzyme prodrug therapies
Walther, R., Rautio, J., & Zelikin, A. N. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.013 · Cited by 288
Anderson, P. L., Liu, A. Y., Castillo-Mancilla, J. R., Gardner, E. M., Seifert, S. M., McHugh, C., Wagner, T., Campbell, K., Morrow, M., Ibrahim, M., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01710-17 · Cited by 272
Remimazolam: non-clinical and clinical profile of a new sedative/anesthetic agent
Kilpatrick, G. J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.690875 · Cited by 262
Argikar, U. A., Potter, P. M., Hutzler, J. M., & Marathe, P. H. (2016) · The AAPS Journal · doi:10.1208/s12248-016-9962-6 · Cited by 89
Vrana, M., Whittington, D., Nautiyal, V, & Prasad, B. (2017) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12170 · Cited by 22
Landry, M. L., Trager, R., Broccatelli, F., & Crawford, J. J. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00071 · Cited by 10
Human Carboxylesterase 2 in Cocaine Metabolism
Figueiredo, P. R., González, R. D., & Carvalho, A. T. P. (2021) · Molecular Catalysis · doi:10.1016/j.mcat.2021.111938 · Cited by 9
Metadata
- Authors
- Casey Laizure, S., Herring, V., Hu, Z., Witbrodt, K., & Parker, R. B.
- Venue
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Publisher
- Wiley
- Published
- 2013-02
- Volume
- 33
- Issue
- 2
- Pages
- 210-222
- ISSN
- 0277-0008 (ISSN-L)
- 1875-9114
- OpenAlex
- W2131257415
- Cited by
- 446
- References
- 68
- FWCI
- 20.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.